Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic

Key Clinical Message Switching to rIX‐FP prophylaxis at dosing intervals of up to 14 days in a hemophilia B pediatric patient decreased treatment burden by reducing the number of administrations and hospital visits, without affecting efficacy or treatment adherence. This is particularly important in...

Full description

Bibliographic Details
Main Authors: Bolívar Luis Díaz‐Jordán, Tamara Cebanu, Sara García Barcenilla, Maria Teresa Álvarez‐Román
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Clinical Case Reports
Subjects:
hemophilia B
pediatrics
prophylaxis
rIX‐FP
Online Access:https://doi.org/10.1002/ccr3.8180

Similar Items

Similar Items